People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Sleep expert Dr. Abhay Sharma talks about how Zepbound is now approved by the FDA for the treatment of moderate to severe ...

Medicare Part D plans cover popular obesity drugs if they are used for an additional medically accepted purpose as approved ...

But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

Using body-mass index to tell who is overweight or obese is not reliable and can result in misdiagnosis, the Commission on ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...

Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on January 13.Stay Ahead of the ...

Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...